cyrilzakka/clinical-trials huggingface dataset:
Overcoming Learned Non-Use in Chronic Aphasia

In this study the investigators are examining the effectiveness of intensive speech therapy in chronic moderate-to-severe stroke-induced aphasia under two conditions - responses "constrained" or unconstrained to speech. Both treatments involve massed practice communicating, using intensive language action therapy 3 hours/day, 5 days/week for two weeks, followed by six months of a home practice program. One treatment stresses spoken responses as the preferred expressive modality during intensive therapy. Before and after treatment, and following the home practice program and a period of no practice, the investigators will administer several tests and discourse samples to examine changes associated with the treatments. Participants will also undergo structural and functional MRI testing at these time points. The investigators will also attempt to quantify the degree to which improvements following intensive language therapy and home practice correlate with changes in Quality of Life measures as perceived by both participants with aphasia and their significant others. It is hypothesized that, whereas both treatments will lead to improvements in naming practiced words and communicating, outcomes will be enhanced for the group randomly assigned to the "constraint" condition. Moreover, performance will be enhanced on words practiced during the home practice program, including those that were not practiced during intensive therapy. Improved naming will correlate with modulation of 'signature' language and attentional networks, whose variability will depend on remaining viable brain structures. Initial severity and site/extent of lesion should predict patients' ability to transfer gains in naming to improvements in discourse.


Eligibility Criteria:
Inclusion Criteria:

* unilateral left hemisphere stroke at least 6 months earlier
* aphasia with moderate-to-severe word retrieval impairments
* at least 21 years of age
* premorbidly right handed
* native speaker of English

Exclusion Criteria:

* history of developmental learning difficulties
* history of prior neurological illnesses
* chronic medical illnesses that restrict participation in intensive therapy
* recent alcohol or drug dependence
* severe uncorrected impairments of vision or hearing
* any contraindication to a 3T MRI procedure (e.g., claustrophobia, metal implants or fragments in body, pregnancy)
Evaluation of Skeletal Muscle Function Using Ultrasonic Elastography

The goal of observational study is to evaluation of skeletal muscle function in patients with chronic obstructive pulmonary disease before and after lung rehabilitation training using ultrasonic elastography in Chronic Obstructive Pulmonary Disease. The main question it aims to answer are:Evaluation of skeletal muscle function in patients with chronic obstructive pulmonary disease before and after lung rehabilitation training using ultrasonic elastography.

Participants will undergo pulmonary rehabilitation.


Eligibility Criteria:
Inclusion Criteria:

* The age is between 40-80 years old
* Patients with chronic obstructive pulmonary disease who meet the diagnostic criteria of GOLD guideline(2019)
* There was no acute exacerbation in the past 12 weeks

Exclusion Criteria:

* Hypoxemia (oxygen partial pressure is less than 60mmHg or oxygen saturation is less than 88% at rest), or patients who need continuous oxygen inhalation, or patients with any contraindication to exercise test (refer to the American Thoracic Association/American Association of Thoracic Physicians exercise test guidelines)
* Oral glucocorticoids
* Receive long-term oxygen therapy prescription
* Have participated in supervised exercise programs in the past 12 months
* History of other lung diseases, including pneumoconiosis, bronchiectasis, tuberculosis, primary pulmonary hypertension, pulmonary embolism, interstitial lung disease
* Diseases that restrict the active exercise ability of participants or involve skeletal, neuromuscular, cardiovascular or metabolic disorders of muscle activity, such as tumors, diabetes, muscle weakness, etc
The Effect of Prayer on Dyspnea Severity, Anxiety and Spiritual Well-Being in Individuals With COPD

This study will be conducted in order to examine the effect of prayer to individuals with COPD on the severity of dyspnea, anxiety and spiritual well-being experienced by patients.

This study will be conducted on people with COPD. People with COPD disease will be divided into two groups. The experimental group will be given a prayer lesson for a month. Prayer listening will not be performed to the control group. At the end of one month, the severity of dyspnea, anxiety and spiritual well-being levels of people in both groups will be re-evaluated.

Eligibility Criteria:
Inclusion Criteria:

* 90 individuals (45 experiments, 45 controls) who can be contacted, who have agreed to participate in the study
* who are literate, can speak Turkish
* who have not participated in a similar application of this study before
* who have agreed to participate in the study after being informed about the research
* are 18 years old and over, with a COPD diagnosis will be taken

Exclusion Criteria:

* Individuals with mental and hearing problems, who have lost a family member and someone close to them in the last year
* who are using tranquilizers/antidepressants
* who have experienced a traumatic situation such as divorce will be excluded from the sample.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

Eligibility Criteria:
Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

- None
Platelet Rich Fibrin and Concentrated Growth Factors on Osseointegration of Immediate Implants

This study will involve 14 patients with mandibular premolars indicated for extraction and immediate replacement. The patients will be randomly allocated into two groups and each patient will receive one implant. In Group A, a CGF membrane will be laid in the implant cavity. While in Group B, a PRF membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.

Resonance frequency measurement will be done using the OSTELL device intraoperatively, at the 1st week and after 3 months. Cone-beam computed tomography will be done preoperatively, immediately following surgery, and after 3 months


Eligibility Criteria:
Inclusion Criteria:

* Cooperative patients with good oral hygiene.
* Patients having a history of mandibular premolars indicated for extraction and immediate replacement.

Exclusion Criteria:

* Heavy smokers.
* Parafunctional occlusal habits.
* Uncontrolled diabetes.
* History of chemotherapy or radiotherapy.
* Hematological disorders that prevent either implantation or centrifugation.
* Pregnancy.
* The nee¬d for additional augmentation or previous augmentation of the same region.
* Chronic periapical pathology
A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block

The aim of this randomized, observer-blinded study is to evaluate the postoperative analgesic efficacy of adding dexamethasone and clonidine to ropivacaine in supraclavicular nerve block. The investigators hypothesized that addition of dexamethasone and clonidine to ropivacaine would prolong the duration of analgesia in supraclavicular nerve block compared with ropivacaine alone.

Subjects undergoing orthopedic surgery of upper extremities were randomized to be one of the three groups to receive supraclavicular nerve block with group 1: ropivacaine alone; group 2: ropivacaine and dexamethasone; group 3: ropivacaine and clonidine or group 4: ropivacaine and dexamethasone and clonidine combination.

Subjects were identified at the day surgery unit at Parkland hospital before the procedure and approached by their physician, the primary investigator, or research personnel for the consent for the study. If the subjects chooses and consents fully to participate, he or she was randomly assigned to receive one of the previously described local anesthetics for supraclavicular nerve block.

The following clinical outcomes were assessed for up to 24 hr: Duration of the block, onset of the block, postoperative pain scores, nausea, vomiting, and complications of peripheral nerve block. Pain was evaluated by using a linear 10-cm visual analog scale (VAS; 0=no pain, 10= worst imaginable pain) immediately before the block, 5, 10, 15 minutes and postoperatively on the arrival of Post Anesthesia Care Unit (PACU) within 15 minutes, discharge from the Day surgery Unit, and 24 hr. later at home via phone call visit.

Sensory and motor block in the related nerve dermatomes were assessed. Patient was instructed to document at what time did hand motion (finger movement) return and what time normal sensation return. Specific time for both events was sked to patient at phone call visit 24 hr later. Overall patient satisfaction was evaluated at the discharge from the day surgery and 24 hr after the block via phone visit.

At any point in which the patient is not experiencing pain relief after having received the injection, they were removed from the study and other anesthetic techniques will be applied to resolve their pain along with pharmacological management of their pain. Rescue antiemetic, which is standard of care, will be given to any patient who complains of nausea or vomiting.

Eligibility Criteria:
Inclusion Criteria:

* Men and women 18-80 years old
* Undergoing upper extremity surgery
* Receiving Supraclavicular block
* Receiving ropivacaine, ropivacaine adjuvants (dexamethasone, clonidine) for the supraclavicular nerve block.
* Able to give Informed consent

Exclusion Criteria:

* Age less than 18 and greater than 80 years
* Inability to understand the study procedures
* Significant respiratory dysfunction
* Preexisting neurologic deficits
* Allergy to local anesthetics
* A bleeding diathesis or on anticoagulants
* Systemic glucocorticoid use
* Refuse to participate in the study
Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy

Iron deficiency anemia (IDA) is common during pregnancy and has adverse effects on the mother, fetus and newborn. Oral iron supplements are usually recommended to prevent ID/IDA during pregnancy.

The aim of this study is to define an iron supplementation schedule with maximal absorption using serum hepcidin profiles and stable iron isotopes in pregnant women. In this randomized, open-label trial, fractional and total iron absorption will be compared from daily dosing with 60 mg iron versus alternate day and every third day dosing with 120 mg iron in pregnant Thai women with low iron stores (n=28) during their second trimester of pregnancy.

This study could have wide impact, providing the evidence base for revised, improved recommendations for iron supplementation during pregnancy.


Eligibility Criteria:
Inclusion Criteria:

* gestational week 14-16 at study start
* singleton pregnancy
* Serum ferritin SF \<60 µg/L
* non-anemic or mildly anemic, defined as hemoglobin (Hb) \>10 g/dL
* female aged 18-45 years
* healthy Thai woman

Exclusion Criteria:

* acute or chronic disease
* taking medications that could influence iron absorption
* smoking
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.


Eligibility Criteria:
Inclusion criteria:

* Patients with age ≥18 years
* Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head \& neck cancer
* No evidence of distant spread of the disease

Exclusion criteria:

* Patients who have severe and/or uncontrolled medical conditions
* Female patients who are pregnant or breast feeding

Other protocol-defined inclusion/exclusion criteria may apply
User Study for Enhanced Meter Feature

This enhanced meter feature raises awareness among patients by providing additional information regarding their glycemic control in between Healthcare Professional visits. This information may facilitate increased dialogue between patient and Healthcare Professional and can remind patients of the importance of glycemic control.

This study will evaluate a user's ability to use the enhanced meter feature.


Eligibility Criteria:
Inclusion criteria:

IC 1. Age of subject is 18 years or older

IC 2. Type I or type II diabetes inclusive of the following populations:

1. Mixed insulin therapies
2. Basal insulin therapies
3. Bolus insulin therapies
4. CSII therapies
5. MDI therapies
6. Non-insulin diabetic treatments (oral and injectable)
7. Life style (exercise and diet) diabetes management IC 3. Able to speak and read English proficiently

Exclusion criteria EC 1. Pregnant EC 2. Hct \<20 or \>60 EC 3. Work for BGM competitor company (including, but not limited to Lifescan, Roche, Abbott) EC 4. Homeless EC 5. Incarcerated EC 6. Institutionalized EC 7. Employees or students of the Research Site, including the Principal Investigator, directly involved in the conduct of the protocol.

EC 8. Has any condition that the Principal Investigator believes may interfere in the subject's participation in the study.

EC 9. Previous experience using the MyStar Extra BGMS
Treatment of Erectile Dysfunction II

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).

Multi-center, randomized, double-blind, placebo-controlled, parallel-group design, Phase 3 pivotal study to investigate the efficacay and safety of 50 mg, 100 mg and 150 mg udenafil tablets compared with placebo in men with ED. This study consisted of a 4-week, treatment free run-in period followed by a treatment period of 12 weeks, with an on-demand dosing regimen.

Eligibility Criteria:
Inclusion Criteria:

* Male, at least 19 years of age
* Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
* Partner is not pregnant or lactating

Exclusion Criteria:

* History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
* Cardiac arrhythmias requiring antiarrhythmic treatment
* Symptomatic congestive heart failure
* Taking nitrate medication in any form
* Uncontrolled diabetes (HbA1c ≥ 13%)
* Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
* Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®
Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis

This project was a Randomized clinical trial conducted to Compare the effects of dry needling and dry cupping in Positional fault of pelvis due to Myofascial trigger points in Quadratus Lumborum so that we can have best treatment option for patients with myofascial trigger points.

Non Probability Convenient sampling was done. Patients following eligibility criteria from Physiotherapy department of Islam Central hospital, Sialkot were considered. Sample size was calculated with Epitool calculator. 26 Participants were randomly allocated in two groups equally via convenient sampling method. Baseline assessment was done initially. Group A was given Dry needling technique and Group B was given Dry Cupping along with conventional physiotherapy treatment (hot pack and stretching). Duration of research was almost 6 months. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum. All participants were provided written informed consent prior to commencement of the procedures. They were free to quit the treatment at any stage of research. Data was analyzed by using SPSS version 23.

Eligibility Criteria:
Inclusion Criteria:

* On palpation the presence of at least 1 active trigger point in quadratus lumborum. So the patient presents with low back pain.
* Patients presents with positional fault of pelvis (lateral tilt)(4).
* Patients having chronic Low Back Pain for at least more than 6 months(3).
* Patients agree to get treatment sessions for the research work.

Exclusion Criteria:

* Participants should not have taken any medications like analgesics, anti-coagulants, Non-steroidal anti-inflammatory drugs or muscle relaxants during this study or even 3 days before this study.
* Participants should not have received any other treatment for the pain management, because it will affect the results of the study.
* Patients with bleeding disorders, local or systemic infection, acute muscle trauma.
* Patients with comorbid conditions.
* Patients with severe physical disability and true leg length discrepancy(1).
* Pregnant females
Prevalence ， Associated Factors and Influences of Prenatal Mental Disorders

The purpose of this study is to find the incidence of mental disorders during different periods of pregnancy and its associated factors and consequences.


Eligibility Criteria:
Inclusion Criteria:

* Aged at least 18 years of age
* 8 to 12 weeks of pregnancy
* There is no history of mental illness
* Had perinatal health care in a Women's \& Children's Health Hospital

Exclusion Criteria:

* The obvious body disease
* Having anxiety, phobia, hypochondriasis, obsessive-compulsive disorder or depression before pregnancy
* Having severe complications during pregnancy
* Fetal malformation or abortion
* Can't understand the questionnaire
* Without informed consent
* More than 13 weeks of pregnancy
* Less than 18 years of age
Pityriasis Lichenoides : Anatomo-clinical Aspects and Follow-up

Introduction: Pityriasis lichenoides (PL) is an inflammatory dermatitis of undetermined origin consisting of specific papular lesions reflecting an "indolent" lymphoproliferative state.

The current classification is confusing because it mixes semiological and chronological notions.

The objectives of this study are to better describe the clinical, epidemiological, histological, phenotypic and evolutionary aspects of PL in an adult population.

Methods: Investigators will perform a retrospective cohort study including patients with clinical and histological diagnosis of PL from the coding of the Department of Pathology of Henri-Mondor Hospital and from medical records and photographs of lesions if available, between January 2012 and August 2018. A follow-up telephone interviews will also be proposed to each patient to collect evolution data. Photographs will be systematically reviewed as well as cutaneous samples and a genomic analysis will be performed.

Conclusion: Investigators would like to better understand clinical, histological features and evolutionary aspects of PL in an adult population.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Patients with Pityriasis Lichenoides selected from histological coding OT0431, seen at Henri Mondor and with a diagnosis verified from medical records.

Exclusion Criteria:

* Histological coding error
* Histological records of patients in care outside Henri Mondor (cases referred for histological expertise only but not seen clinically)
* Clinical lesions incompatible with Pityriasis Lichenoides according to classically published semiological data
* Missing or insufficient medical records for data exploitation
Speech Groups for Children Living with a Sibling Who Suffers from Anorexia Nervosa

Anorexia nervosa (AN) is a complex mental disease with a huge impact on the patient's siblings life and well-being. Based on literature, group interventions for siblings of children suffering from a chronic disease could provide an effective support. A few have been studied, and even fewer exist for siblings of children with AN.

AN has a significant impact on nuclear family (parents and siblings). An emerging literature highlights the need for a particular attention to siblings. Despite this evidence, research and clinical applications still lack in this area. Indeed, most of health services in AN offer support for patients, family, parents, but only few specific support for siblings, although positive outcomes of sibling group interventions were reported in other somatic and psychic disabilities.

Noting the gap between the need and the lack of specific support, the study hypothesis is that the poor diffusion of these interventions in AN might result from a low acceptability. The study propose to explore acceptability to adapt and improve group intervention for siblings of children and teenagers receiving care for anorexia nervosa.

The study is a mixed-method pilot study assessing the acceptability of a group intervention by including a maximum of 24 siblings of children suffering from AN, aged from 8 to 18, across three group sessions, each consisting of 4 meetings. All participants will be invited to fulfill two different auto-questionnaires about their quality of life (before and after group session) and the intervention's acceptability (after group session).

Quantitative data will be complemented with qualitative data, collected from individual semi-structured interviews with a targeted sampling among group participants.

Eligibility Criteria:
* inclusion criteria : Sibling presenting a DSM (Diagnostic and Statistical Manual)-5 of Mental Disorders diagnosis of AN, and engaged in inpatient or outpatient healthcare
* exclusion criteria :

  * (1) Opposition from the participant and/or from their legal representatives.
  * (2) Non-fluent French speaker
  * (3) Clinical presentation not compatible with the group sessions